Aardvark Therapeutics Inc (AARD)

Apr 02, 2025

Aardvark Therapeutics (NASDAQ:AARD) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World

Apr 02, 2025

Apr 01, 2025

Cantor Fitzgerald maintains $50 target on Aardvark Therapeutics stock - Investing.com Australia

Apr 01, 2025

Apr 01, 2025

RBC Capital maintains $21 target on Aardvark Therapeutics stock - Investing.com

Apr 01, 2025

Mar 31, 2025

Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights - The Manila Times

Mar 31, 2025

Mar 28, 2025

BofA lifts Aardvark Therapeutics target to $26, maintains Buy By Investing.com - Investing.com Canada

Mar 28, 2025

Mar 27, 2025

Positive Outlook for Aardvark Therapeutics Amid Favorable Regulatory and Market Conditions - TipRanks

Mar 27, 2025

Mar 27, 2025

Aardvark Therapeutics price target raised to $26 from $22 at BofA - TipRanks

Mar 27, 2025

Mar 27, 2025

BofA lifts Aardvark Therapeutics target to $26, maintains Buy - Investing.com India

Mar 27, 2025

Mar 21, 2025

Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory (NASDAQ:SLNO) - Seeking Alpha

Mar 21, 2025

Mar 14, 2025

Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month - Yahoo Finance

Mar 14, 2025

Mar 12, 2025

Top 10 Insider Purchases Last Month - Insider Monkey

Mar 12, 2025

Mar 11, 2025

Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Royal Bank of Canada - Defense World

Mar 11, 2025

Mar 11, 2025

Aardvark Therapeutics (NASDAQ:AARD) Coverage Initiated by Analysts at Bank of America - Defense World

Mar 11, 2025

Mar 11, 2025

BofA sets Aardvark Therapeutics stock with $22 target By Investing.com - Investing.com Australia

Mar 11, 2025

Mar 11, 2025

Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Morgan Stanley - Defense World

Mar 11, 2025

Mar 11, 2025

Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Analysts at Cantor Fitzgerald - Defense World

Mar 11, 2025

Mar 10, 2025

BofA Initiates Aardvark Therapeutics at Buy With $22 Price Target -March 10, 2025 at 10:01 am EDT - Marketscreener.com

Mar 10, 2025

Mar 10, 2025

RBC Capital sets Aardvark Therapeutics at Outperform - Investing.com

Mar 10, 2025

Mar 10, 2025

This Pulmonx Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Mar 10, 2025

Mar 10, 2025

RBC Capital sets Aardvark Therapeutics at Outperform By Investing.com - Investing.com South Africa

Mar 10, 2025

Mar 10, 2025

Aardvark Therapeutics initiated with an Overweight at Cantor Fitzgerald - TipRanks

Mar 10, 2025

Mar 10, 2025

Morgan Stanley Initiates Aardvark Therapeutics at Overweight -March 10, 2025 at 08:13 am EDT - Marketscreener.com

Mar 10, 2025

Mar 10, 2025

Cantor Fitzgerald Initiates Aardvark Therapeutics at Overweight With $50 Price Target -March 10, 2025 at 08:03 am EDT - Marketscreener.com

Mar 10, 2025

Mar 10, 2025

BofA sets Aardvark Therapeutics stock with $22 target - Investing.com India

Mar 10, 2025

Mar 10, 2025

RBC Initiates Aardvark Therapeutics at Outperform With $21 Price Target, Speculative Risk Qualifier - Marketscreener.com

Mar 10, 2025

Mar 10, 2025

Morgan Stanley sets Aardvark stock target at $29, rating Overweight By Investing.com - Investing.com South Africa

Mar 10, 2025

Mar 10, 2025

Morgan Stanley sets Aardvark stock target at $29, rating Overweight - Investing.com

Mar 10, 2025

Mar 04, 2025

San Diego had its first biotech IPO of 2025. Are more on the way? - MSN

Mar 04, 2025

Mar 03, 2025

Aardvark Therapeutics’ $94.2 Million Initial Public Offering - Global Legal Chronicle

Mar 03, 2025

Mar 03, 2025

Aardvark Therapeutics (AARD): Among Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey

Mar 03, 2025

Feb 24, 2025

IPOs Numbers Rise In 2024, But Dwindling Returns Could Diminish Potential In 2025 - Scrip

Feb 24, 2025

Feb 23, 2025

Biotechs Highlight 6 Stocks Insiders Are Buying Now - 24/7 Wall St.

Feb 23, 2025

Feb 21, 2025

Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight - GlobeNewswire Inc.

Feb 21, 2025

Feb 20, 2025

Big Moves: Major Stakeholders Invest Heavily in Aardvark Therapeutics - TipRanks

Feb 20, 2025

Feb 20, 2025

Autism Spectrum Disorder Treatment Market Size is expected - openPR

Feb 20, 2025

Feb 20, 2025

Aardvark therapeutics sees $20m stock purchase by Decheng capital - Investing.com India

Feb 20, 2025

Feb 18, 2025

DAC specialist Orum raises $35M with Kosdaq IPO - BioWorld Online

Feb 18, 2025

Feb 17, 2025

Finance Watch: Investors’ Appetite For Aardvark Wanes After $94.2m IPO - News & Insights

Feb 17, 2025

Feb 15, 2025

Orum, Aardvark IPOs trade in opposite directions: Public Equity Report - biocentury.com

Feb 15, 2025

Feb 14, 2025

Aardvark stock slides 11% following $94M IPO - MSN

Feb 14, 2025

Feb 13, 2025

Aardvark stock slides 11% following $94M IPO (AARD:NASDAQ) - Seeking Alpha

Feb 13, 2025

Feb 13, 2025

Aardvark Therapeutics prices $94M IPO at $16 per share - MSN

Feb 13, 2025

Feb 13, 2025

Aardvark Lands $94M IPO as Biotech Wave Gains Momentum - USA Herald

Feb 13, 2025

Feb 13, 2025

Aardvark Therapeutics Shares Below IPO Price on Nasdaq Debut -February 13, 2025 at 12:17 pm EST - Marketscreener.com

Feb 13, 2025

Feb 13, 2025

Paul Hastings, Cooley Lead Obesity-Focused Aardvark's IPO - Law360

Feb 13, 2025